Table 1

 Baseline characteristics of patients

CharacteristicsPlaceboInfliximab 5 mg/kg
*Unless otherwise specified, data are expressed as means.
PsA, psoriatic arthritis; BSA, body surface area; PASI, Psoriasis Area and Severity Index; VAS, visual analogue scale; HAQ, Health Assessment Questionnaire; PCS, physical component summary; MCS, mental component summary; SF-36, Short Form-36.
Age (years), mean (SD)46.5 (11.3)47.1 (12.8)
Sex, male (%)51 (51)71 (71)
Race, white (%)94 (94)95 (95)
Baseline disease characteristics*
PsA duration (years)7.58.4
Psoriasis duration (years)16.816.2
Patients with at least 3% BSA psoriasis involvement (%)87/98 (89)83/100 (83)
PASI score (0–72)10.211.4
Number of swollen joints (0–66)14.413.9
Number of tender joints (0–68)25.124.6
Duration of morning stiffness (0–1440 min)183.4216.0
Patient’s assessment of pain (VAS; 0–10 cm)5.95.6
Physical function/quality of life*
HAQ score (0–3)1.11.1
PCS score of SF-3631.033.0
MCS score of SF-3647.045.5